RPRXRoyalty Pharma plc
Is it safe?
Strong, no red flags: a safe balance sheet and steady price behavior.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$13.0M, 90 days to Oct 22, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Relatively steady, low volatility. Worst drawdown -50% · now at/near its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can RPRX take a bad year?
Royalty Pharma plc carries $8.12B of net debt at 5.36× EBITDA: a heavy load to carry through a bad year.
Net debt · as at Q2 2026 · over four years of earnings before interest, tax and depreciation, heavy
- Net debt / EBITDA
- 5.36×
Net debt / EBITDA
- Altman Z-score
- 2.83
Altman Z-score · grey zone, between 1.8 and 3
- Interest cover
- 4.19×
Interest cover · operating profit covers the interest bill, with room to spare
Details›
- Total debtQ2 2026
- $8.96B
- Cash and short-term investments
- $837M
- Net debt
- $8.12B
- EBITDA, trailing twelve months
- $1.52B
- Operating profit, trailing twelve months
- $1.51B
- Debt / equity
- 0.92×
- Total debt / EBITDA
- 5.91×
- Annualised volatilitytwo years of daily moves
- 24%
- Worst drawdown on file
- −50%
- Below its 52-week high
- 0.21%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
The balance sheet
What it owes against what it owns, and how close that comes to trouble.
How far can it fall?
How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.